A phase I-II study of intensive-dose XXXX for advanced @entity0 .

@entity1 @entity632 @entity137 @entity0 @entity41 @entity1370 @entity2145
Twenty-six @entity1 with @entity0 were treated with intensive @entity632 (Adria Laboratories, Columbus, @entity2145 ) as a single agent administered for three successive days once a month. Dosing started at 25 or 30 mg/m2/d three times, and was escalated by 5 mg/m2/d monthly to maximal tolerance based on hematologic, mucosal, or cardiac @entity137 . Four @entity1 (15%) had complete remissions (CRs) pathologically proven, and six others (23%) sustained complete CRs, but were found to have microscopic @entity41 (three) or refused biopsy (three). Twelve @entity1 (46%) attained partial remission (PR). The overall response (85%) and CR rates (38%) were approximately double those reported with conventional @entity632 doses. Median unmaintained remission duration for the ten @entity1 in CR was 11 months. @entity1370 , determined by radionuclide physiologic studies, occurred in 16 @entity1 at a mean dose of 459 mg/m2; three @entity1 developed reversible congestive failure. There were no toxic deaths. The median overall survival was 18 months. These data suggest that there is steep dose responsiveness to @entity632 in @entity0 , and that more effective techniques for using @entity632 may exist than those conventionally used.
